

Index

A

- AAI. *See* Ankle-arm index (AAI)
- Abdominal aortic aneurysm, 396–397
conclusions, 5t, 27, 397, 407
epidemiologic evidence, 396, 398t–407t
evidence synthesis, 397
implications, 397
- Abortion, spontaneous. *See* Spontaneous abortion
- Absenteeism, 615, 626–646, 638t–645t, 648t–653t
- Absolute measures, *versus* relative, 884
- Acquired immunodeficiency syndrome (AIDS). *See* HIV infection
- ACS. *See* American Cancer Society (ACS)
- Acute leukemia, 26, 252–254, 905
biologic basis, 252–253
conclusions, 4t, 26, 254, 325
epidemiologic evidence, 253–254, 258t–295t
implications, 254
mortality rate, 253
- Acute respiratory diseases, 423–463. *See also* specific disease
biologic basis, 424–428
classification of, 423
conclusions, 27, 424, 447, 508
with COPD, 447–463
conclusions, 462
epidemiologic evidence, 447–462, 450t–454t
evidence synthesis, 462
implications, 462–463
immune response markers in, 425, 426t–428t, 427
mortality rate, 424
without COPD, 428–447
epidemiologic evidence, 428–444, 429t–431t
evidence synthesis, 444–445
implications, 447, 448t
- Adenocarcinoma
colorectal, 210, 211
esophageal, 116, 117, 118, 119, 122t–127t, 130t–133t, 181, 324
gastric, 180, 181
kidney, 166
lung, 43, 48, 59–61, 324
pancreatic, 136
- Adenomas, colorectal, 210–213, 216t–227t
- Adolescence
asthma in (*See* Asthma)
chronic respiratory symptoms in, 6t, 27–28, 485–488
evidence synthesis, 464t, 485–486
lung function in, 6t, 27–28, 473–474
smoking prevalence rates, 215, 859, 859t, 897–898
smoking reduction efforts, 871, 872, 872t
- Advertising, cigarette, 899
- African Americans
breast cancer, 308
cerebrovascular disease, 395
esophageal cancer, 116
lung cancer, 60f
oropharyngeal cancer, 63
prostate cancer, 250
- Age at onset of smoking
and breast cancer, 303, 306–307
and colorectal cancer, 213, 244t–249t
and infertility, 535
and lung cancer, 44
- Age distribution. *See also* Child(ren); Elderly population
absenteeism, 637, 646
atherosclerosis, 372–373
bone mass, 698–699 (*See also* Bone mineral density (BMD))
cerebrovascular disease, 393–394
COPD, 499
coronary heart disease, 384–385
dental disease, 738
erectile dysfunction, 767
fracture risk, 717–718, 717f
leukemia, 252
lung cancer, 58t, 60f
lung function decline, 474, 480–481, 481f
medical services utilization, 647, 652–653
prostate cancer, 250
smoking attributable mortality, 863, 880, 881t, 882
former smokers, 874, 882
smoking prevalence rates, 872–873, 872t–873t, 876
- Age-related macular degeneration (AMD), 777, 780–781, 786–788
biologic basis, 781
conclusions, 29, 788
epidemiologic evidence, 786–787, 790t–795t
evidence synthesis, 787–788
implications, 788
- AIDS. *See* HIV infection
- Airflow limitation, chronic, 469
- Airflow obstruction, in COPD, 498
- Alabama, medical care costs study in, 647
- Alcohol consumption
absenteeism, 636–637
breast cancer, 306–307
colorectal cancer, 214

Note: t following a number refers to a Table; f following a number refers to a Figure.

- esophageal cancer, 116, 119, 134t–135t
 - laryngeal cancer, 62, 80t–97t, 324
 - liver cancer, 296–297
 - oropharyngeal cancer, 63–64, 66, 67, 110t–115t, 882–884
 - pancreatic cancer, 137
 - stomach cancer, 181
 - Alpha₁-antitrypsin deficiency, 672
 - AMD. *See* Age-related macular degeneration (AMD)
 - American Cancer Society (ACS), 881t
 - cancer prevention studies (*See* Cancer Prevention Study I (CPS-I); Cancer Prevention Study II (CPS-II))
 - American Legacy Foundation, 863, 869
 - Analogy, 22
 - Androgen receptors, 250
 - Aneurysm, abdominal aortic. *See* Abdominal aortic aneurysm
 - Angina pectoris, 384
 - Animal studies
 - atherosclerosis, 365–366, 368, 370
 - bladder and kidney cancer, 166
 - breast cancer, 304
 - colorectal cancer, 211
 - erectile dysfunction, 768, 775–776, 775t
 - esophageal cancer, 118–119
 - leukemia, 252–254
 - macular degeneration, 787
 - oropharyngeal cancer, 64, 65, 67
 - oxidative stress, 619
 - pancreatic cancer, 136
 - reproductive effects, 534, 563, 564
 - respiratory diseases, 424–425, 444
 - stomach cancer, 181
 - Ankle-arm index (AAI), 372–373, 372t, 379, 380t–381t
 - Anthropometric characteristics, and lung function decline, 479, 483, 484f
 - Antibiotics
 - for acute bronchitis, 460–462
 - for COPD exacerbations, 451–452, 453–455, 456t–461t, 458t–461t, 460, 462
 - for *H. pylori* infection, 181, 183
 - Antioxidants
 - and cataractogenesis, 778
 - depletion of, 619
 - Antiproteases, 472–473
 - Antithrombin III, 368
 - Aortic aneurysm, abdominal. *See* Abdominal aortic aneurysm
 - APC gene, 180, 210
 - L-arginine, 366
 - Arizona
 - infant lung development study in, 468
 - lung function decline study in, 474, 479
 - tobacco control program, 875
 - Arrhythmias, 387
 - Asbestos exposure, 465t
 - Association
 - relative versus absolute measures of, 884
 - strength of, 21
 - Asthma, 462–463, 486–487, 490–491, 498
 - in childhood, 486–487
 - and lung function decline, 27–28, 478
 - Atherogenesis, 364–369, 365f
 - stages of, 371–373, 384
 - Atherosclerosis. *See also* Coronary heart disease and abdominal aortic aneurysm, 396–397
 - biological markers of, 366–368, 372–373, 372t, 378–379, 382t–385t
 - conclusions, 5t, 26
 - coronary, 373, 378–379
 - inflammatory response in, 368, 370
 - pathogenesis of, 364–369, 365f, 371–372, 384
 - subclinical (*See* Subclinical atherosclerosis)
 - and sudden cardiac death, 387
 - symptoms of, 371
 - Atherosclerosis Risk in Communities (ARIC) Study, 372
 - Attributable risk, 3, 19. *See also* Population-attributable risk (PAR)
 - Australia
 - absenteeism studies in, 627
 - brain cancer studies in, 302
 - infant lung development study in, 468
 - ovarian cancer study in, 171
 - peptic ulcer disease study in, 805
 - sudden cardiac death study in, 387
-
- ## B
- “Back to Sleep” campaign, 584
 - Bacterial infection, dental diseases caused by, 733–734, 736
 - B₂-adrenergic receptor gene, 697
 - Bank of America study, 662
 - Barrett’s esophagus, 117, 181
 - Bcl-2* gene, 180
 - Behavioral Risk Factor Surveillance System (BRFSS), 863, 885
 - Benzene, 252, 254
 - Benzo[a]pyrene, 210, 211, 616
 - Best Practices for Comprehensive Tobacco Control Programs* (CDC), 899
 - Betel, 63, 67
 - Bias
 - in cataract studies, 779
 - in peptic ulcer disease studies, 807
 - Bicarbonate, 805
 - Biological markers. *See also* specific marker or disease
 - atherosclerosis, 366–368, 372–373, 372t, 378–379, 382t–385t
 - bone mass loss, 698–699
 - breast cancer, 304, 308, 312
 - cancer, 39
 - lung, 44–47, 49
 - and cigarette type, 51
 - esophageal cancer, 117
 - inflammatory, 368, 370, 626, 634t–637t
 - lung function decline, 479–480

- macular degeneration, 786
 oropharyngeal cancer, 65
 oxidative injury, 619, 620t–625t
 respiratory infections, 425, 426t–428t, 427
 thrombosis, 367–368
- Biologic basis.** *See also specific disease or condition and causal inference, 20, 22, 899–900*
- Biologic gradient, 22.** *See also Dose-response relationship*
- Birth weight**
 low (*See Low birth weight (LBW); Very low birth weight (VLBW)*)
 and smoking during pregnancy, 469, 1395, 1404–1405, 1414–1415
- Bladder cancer, 166–167, 905**
 conclusions, 4t, 26, 39, 40t, 166–167, 324
- Blindness.** *See Age-related macular degeneration (AMD); Glaucoma*
- Blood pressure, 369–370**
 high (*See Hypertension*)
 measurement of (*See Ankle-arm index (AAI)*)
- Blood rheology, increased, 369–371**
- Body mass**
 and breast cancer, 306–307
 and lung function decline, 479, 483, 484f
- Bogalusa Heart Study, 378–379, 396**
- Bone cancer.** *See also specific type*
 conclusions, 39
- Bone mineral density (BMD), 698, 909**
 loss of, 698–717, 818
 age-related, 699
 biologic basis, 698–699
 conclusions, 8t, 29, 698, 715–716
 epidemiologic evidence, 699, 700t–713t, 714, 716
 evidence synthesis, 715–716
 implications, 715–716
 measures of, 699
 in middle and later years, 706t–709t, 710t–713t, 716–717
 peak, 699, 700t–705t, 714, 715f
 in postmenopausal women, 699, 715f, 716–717
 in premenopausal women, 715f, 716
 smoking cessation and, 714
 in young people, 699–715, 700t–713t
- Boston (Massachusetts) study**
 chronic respiratory symptoms, 488
 lung function, 474
- Brain, MRI of, in subclinical atherosclerosis, 373, 379, 382t–385t**
- Brain cancer, 302–303, 905**
 conclusions, 26, 302–303, 325
 mortality rate, 302
- BRCA1 gene, 309, 312, 325**
- BRCA2 gene, 309, 312, 325**
- Breast cancer, 303–312, 905–906**
 biologic basis, 304–305, 900
 conclusions, 26, 303–304, 312, 325
 epidemiologic evidence, 305–312, 313f, 314t–323t
 evidence synthesis, 312
 implications, 312
 mortality rate, 311–312
 risk assessment, 305–307
 screening prevalence, 311–312, 318t–319t
- Breastfeeding, 527, 563**
- BRFSS.** *See Behavioral Risk Factor Surveillance System (BRFSS)*
- British Physicians Study, 857**
 abdominal aortic aneurysm, 396
 bladder and kidney cancer, 167
 cerebrovascular disease, 394
 colorectal cancer, 212
 esophageal cancer, 118
 leukemia, 253
 liver cancer, 297
 prostate cancer, 251
- British Regional Heart Study, cerebrovascular disease, 394**
- Bronchial hyperreactivity**
 and asthma, 491
 gender difference in, 475, 480
 and lung function decline, 480, 483
- Bronchitis, 449, 451, 452–453, 453–454**
 acute, antibiotic treatment for, 460–462
 in COPD, 498
- Bronchoalveolar lavage (BAL), biomarkers in, 427, 428t**
- Bruch's membrane, 780–781**
- Burden of disease.** *See Disease burden*

C

- Cadmium, 563**
- CAG repeat gene, 250**
- CAL.** *See Clinical attachment level (CAL)*
- Calcium, coronary, 378, 379**
- California**
 brain cancer studies in, 302
 chronic obstructive pulmonary disease studies in, 499–500
 health status study in, 662
 prostate cancer study in, 251
 tobacco control program, 874
- Canada**
 breast cancer study in, 309
 self-rated health status study in, 663
- Canadian Mammography Screening Trial, 173**
- Canadian National Population Health Study, 487**
- Cancer, 35–325.** *See also specific type*
 biological markers of, 39
 conclusions, 4t–5t, 25–26, 40t–41t, 324–325
 smoking attributable mortality, 39, 858, 860t–861t, 861, 862t, 879–880, 882, 884–885, 886t
 summary, 324
- Cancer Prevention Study I (CPS-I), 39, 42, 857**
 abdominal aortic aneurysm, 396
 chronic respiratory disease, 502
 COPD mortality, 500
 coronary heart disease, 386
 cost-of-illness data, 865

- leukemia, 253
- lung cancer, 58t, 60
- medical services utilization data, 647
- smoking attributable mortality data, 859–860, 863, 879, 880, 881t
- Cancer Prevention Study II (CPS-II), 39, 42, 857
 - breast cancer, 311
 - cerebrovascular disease, 393–394, 395
 - colorectal cancer, 212–215
 - COPD mortality, 500
 - coronary heart disease, 386
 - esophageal cancer, 118
 - lung cancer, 58t, 60
 - oropharyngeal cancer, 66
 - prostate cancer, 251
 - smoking attributable mortality data, 859–860, 863, 879, 880, 881t, 882, 884, 885, 886
 - stomach cancer, 183
- Carbon monoxide, 50–51
 - and coronary heart disease risk, 386
 - and diabetic retinopathy, 788
 - effect on cardiovascular function, 369–371
 - pharmacokinetics of, 616
- Carcinogenesis
 - bladder and kidney cancer, 166–167
 - breast cancer, 304, 308
 - cervical cancer, 168, 170
 - colorectal cancer, 210–211, 213–214
 - endometrial cancer, 173
 - esophageal cancer, 117–118
 - leukemia, 252–253
 - liver cancer, 296
 - lung cancer, 43–47, 45f, 61
 - oropharyngeal cancer, 65
 - ovarian cancer, 171
 - pancreatic cancer, 136–137
 - prostate cancer, 250
 - stomach cancer, 180
- Cardiac death, sudden, 384–392
 - epidemiologic evidence, 387
- Cardiovascular diseases, 361–407, 907. *See also specific disease*
 - biologic basis, 364–371, 900
 - conclusions, 5t, 26–27, 363–364, 407
 - and erectile dysfunction, 771
 - mortality rate, 363, 876
 - smoking attributable mortality, 858, 860t, 861, 862t, 880, 881t, 882, 885, 886t
 - summary, 397, 406
- Cardiovascular function, smoking and, 369–371
- Carolina Breast Cancer Study, 309
- Carotenoids, depletion of, 619
- Carotid B-mode ultrasonography, in atherosclerosis studies, 374t–379t
- Carotid intimal-medial thickness (IMT), 372, 374t–379t
- Case-control studies. *See also specific study*
 - abdominal aortic aneurysm, 396
 - asthma, 491
 - bladder and kidney cancer, 166–167
 - brain cancer, 302
 - breast cancer, 306–307, 308–311, 313f, 314t–319t, 322t–323t
 - cataracts, 779, 782t–787t
 - cerebrovascular disease, 394
 - cervical cancer, 169
 - colorectal cancer, 211–212, 236t–239t
 - coronary heart disease, 386, 387
 - endometrial cancer, 173
 - esophageal cancer, 118–119, 122t–127t, 130t–135t
 - fractures, 718, 720t–731t
 - idiopathic pulmonary fibrosis, 503
 - laryngeal cancer, 62, 68t–97t
 - leukemia, 253–254, 258t–277t
 - liver cancer, 296
 - macular degeneration, 787
 - oropharyngeal cancer, 98t–115t
 - ovarian cancer, 171
 - pancreatic cancer, 137, 154t–165t
 - peptic ulcer disease, 807, 810
 - periodontal disease, 735, 740t–741t
 - reproductive effects, 534–535
 - respiratory disease
 - acute, 449–451
 - chronic, 488
 - lower, 438
 - stomach cancer, 182, 188t–191t, 196t–199t, 206t–209t
 - tar and nicotine yield, 51
- Case series, on erectile dysfunction, 769
- Cataracts, 777–780
 - biologic basis, 778
 - conclusions, 8t, 29, 778, 780
 - epidemiologic evidence, 778–780, 782t–787t
 - evidence synthesis, 780
 - implications, 780
- Catecholamines, 369, 387
- Causal claims, 3. *See also specific disease*
 - classification of, 3, 18
 - implications of, 18–19
 - separation from public health recommendations, 24
 - terminology of, 10, 11t–17t, 17–18, 24
- Causal inference, 3, 10–24, 905
 - criteria for, 10, 17, 21
 - application of, 23
 - from experimental data, 17, 19, 22–23
 - judgment in, 19–23
 - from observational studies, 17, 19–21
 - statistical testing and, 23–24
- Causality, reverse, 372
- Causal pathways, linking smoking to poor health status, 615, 676
- Cemento-enamel junction (CEJ), 732
- Centers for Disease Control and Prevention (CDC), 210, 858
 - Best Practices for Comprehensive Tobacco Control Programs*, 899
 - cost-of-illness data, 867, 868t, 869, 869t

- Office on Smoking and Health, 9, 735, 737
 SAM and YPLL estimates, 885
 Smoking-Attributable Mortality, Morbidity, and Economic Costs (SAMMEC), 19, 879, 880, 882, 884, 885, 886, 887
 smoking reduction goals, 872, 872t–873t, 875t
 Centers for Medicare & Medicaid Services, 867
 Cerebral hemorrhage, 394
 Cerebrovascular disease, 393–395. *See also specific disease*
 conclusions, 5t, 27, 395, 407
 epidemiologic evidence, 394–395
 mortality rate, 393–394, 880, 881t, 882, 885
 Cervical cancer, 167–170
 conclusions, 4t, 26, 168, 170, 324
 diagnosis of, 167, 169
 Cervical intraepithelial neoplasia, 168–169
 CHD. *See* Coronary heart disease
 Chewing tobacco. *See* Smokeless tobacco
 CHF. *See* Congestive heart failure (CHF)
 Child(ren). *See also* Adolescence; Infancy
 asthma in, 486–487
 cancer in, 39
 chronic respiratory symptoms in, 6t, 27–28, 485–488
 evidence synthesis, 464t, 485–486
 leukemia in, 252
 lung function in, 6t, 27–28, 463, 464t, 473–474
 passive smoking in, 463, 898
 smoking attributable mortality, 887
 Child development, 576–599
 conclusions, 28, 532t, 599, 600
 epidemiologic evidence, 585–599, 593t–598t
 China
 esophageal cancer studies, 117, 118, 119
 peptic ulcer disease study in, 807
 stomach cancer study in, 180
Chlamydia pneumoniae infection, 432–433, 433t–437t
 Cholesterol levels, 365–366, 368–369
 Choriocapillaris, 780
 Chromosomal abnormalities
 and leukemia, 253
 miscarriage caused by, 551
 Chronic obstructive pulmonary disease (COPD), 423, 498–501
 and acute respiratory disease, 447–463
 biomarkers of, 479–480
 bronchitis with, 460–462
 conclusions, 5t, 27–28, 464t–465t, 501
 epidemiologic evidence, 447–462, 450t–454t, 498–501
 evidence synthesis, 501
 exacerbations, antibiotic prophylaxis for, 451–452, 456–460, 456t–461t, 458t–461t
 implications, 501
 morbidity, 499–500
 mortality, 500–501, 860t, 882, 885, 886t
 and postoperative complications, 653
 and smoking during childhood/adolescence, 473
 Chronic respiratory diseases, 463–508. *See also specific disease*
 biologic basis, 463, 467
 conclusions, 27–28, 463, 464t–467t, 508–509
 risk of, and cigarette type, 501–503, 504t–507t
 CI. *See* Confidence interval (CI)
 Cigarettes smoked per day. *See* Dose-response relationship
 Cigarette type. *See also* Filter-tipped cigarettes; Nicotine yield; Tar yield; Unfiltered cigarettes
 biological markers and, 51
 brain cancer, 302–303
 coronary heart disease risk, 386, 388t–393t, 392
 lung cancer, 48–51, 50f, 52t–57t, 56–57, 59, 61
 pregnancy complications, 50
 respiratory disease
 acute, 444
 chronic, 501–503, 504t–507t
 Cigarette-years, definition of, 735. *See also* Pack-years
 Cigar smoking
 esophageal cancer, 116–117
 health effects, 3
 heart disease risk, 370
 oropharyngeal cancer, 63–64, 66–67
 smoking attributable mortality, 882
 Clinical attachment level (CAL), 733, 735, 736
 Clinical trials, of antibiotic treatment for pulmonary disease, 450–462
 Clotting, 367–368, 370
 Coagulation, 367–368, 370
 Coal dust exposure, 466t
 Codes, disease, 858, 861, 880, 883t
 Coffee consumption, and infertility, 535
 Cognitive development, child. *See* Child development
 Coherence, 22
 Cohort studies, 3. *See also specific study or disease*
 abdominal aortic aneurysm, 396
 absenteeism, 627, 638t–645t, 648t–653t
 atherosclerosis, 372, 379
 bladder and kidney cancer, 166–167
 bone density, 699, 710t–713t, 714, 716
 breast cancer, 306, 310, 311, 313f, 320t–321t
 cataracts, 779–780, 782t–787t
 cerebrovascular disease, 393–395
 cervical cancer, 169
 childhood asthma, 487
 colorectal cancer, 209–210, 212–214, 228t–235t, 240t, 249t
 COPD, 499
 coronary heart disease, 385–386
 dental caries, 737, 738, 763t–766t
 diabetic retinopathy, 788
 endometrial cancer, 173
 erectile dysfunction, 769
 esophageal cancer, 118–119, 120t–121t, 128t
 fractures, 718, 720t–731t
 generalizability of, 884
 hospitalization rates, 647

- leukemia, 253–254, 278t–295t
 - leukocyte counts, 626, 634t–637t
 - liver cancer, 296
 - lung function decline, 475, 476t–479t
 - in childhood, 473–474
 - medical services utilization, 647, 654t–661t
 - oropharyngeal cancer, 65–66, 98t, 102t–103t, 106t
 - pancreatic cancer, 137, 138t–153t
 - peptic ulcer disease, 807, 810
 - periodontal disease, 735, 760t–762t
 - prostate cancer, 250–252, 255t–257t
 - respiratory disease
 - acute, 444, 449, 453
 - chronic, 485, 501–502, 502t–505t
 - risk assessment using, 857
 - smoking attributable mortality, 880, 881t, 882, 884, 885
 - stomach cancer, 181–182, 184t–187t, 192t–195t, 200t–205t
 - tar and nicotine yield, 51
- Collaborative Group on Hormonal Factors in Breast Cancer, 307**
- Colorectal cancer, 208–215, 906**
 - biologic basis, 210, 900
 - conclusions, 26, 209–210, 215, 325
 - epidemiologic evidence, 211–213, 216t–249t
 - evidence synthesis, 213–215
 - implications, 215
 - mortality rate, 208–209, 212–215, 244t–245t
 - screening prevalence, 214–215
- Community Periodontal Index of Treatment Needs, 735**
- Community Preventive Services Task Force, 899**
- Comparability ratios, 861, 883t**
- Computed tomography (CT), of coronary calcium, 378, 379**
- Conception. See Fertility; Pregnancy**
- Conclusions. See also specific disease or conclusion**
 - implications of, 18–19
 - Surgeon General's reports, 3, 4t–8t, 25–30, 899–900
 - terminology of, 10, 11t–17t, 17–18, 24
- Confidence interval (CI), 884**
- Confounding factors, 20, 900**
 - cataract studies, 779
 - colorectal cancer studies, 214
 - coronary heart disease studies, 386–387
 - dental caries studies, 738
 - diminished health status studies, 615, 636–637, 676
 - pancreatic cancer studies, 137
 - PAR estimates, 879
 - periodontal disease studies, 735
 - prostate cancer studies, 250
 - reproductive effects studies, 532, 535, 539, 565
 - smoking attributable mortality estimates, 870, 882, 884
- Congenital malformations, 527, 576–599. See also specific disorder**
 - conclusions, 28, 531t, 599, 600
 - epidemiologic evidence, 576, 577t–584t, 583
- Congestive heart failure (CHF), 387, 392**
- Connecticut Tumor Registry, 60**
- Consistency, 21**
- Constitutional hypothesis, 21**
- COPD. See Chronic obstructive pulmonary disease (COPD)**
- Copenhagen City Heart Study, 449, 478, 491, 501**
- Coronary atherosclerosis, 373, 378–379**
- Coronary calcium, 378, 379**
- Coronary Drug Project, 647**
- Coronary heart disease, 384–392. See also Atherosclerosis; Myocardial infarction (MI)**
 - conclusions, 5t, 27, 392, 407
 - epidemiologic evidence, 384–387
 - evidence synthesis, 392
 - implications, 392
 - and lung function decline, 478
 - mortality rate, 363, 384
 - pathophysiology of, 366, 369
 - percutaneous procedures for, 385–386
 - and postoperative complications, 653
 - risk factors, 363–364, 386–387
- Costs. See Disease burden; Economic costs**
- Cotinine, 51, 550–551, 591**
- Cough, 485, 488, 489f**
- Counterfactual state, 19–20**
- Cox proportional hazard model, in PAR calculations, 879**
- CPS-I. See Cancer Prevention Study I (CPS-I)**
- CPS-II. See Cancer Prevention Study II (CPS-II)**
- C-reactive protein, 368, 370**
- Cross-sectional studies. See also specific study or disease**
 - abdominal aortic aneurysm, 396
 - asthma, 490–491, 494t–497t
 - childhood, 487
 - atherosclerosis, 372, 373, 379, 397
 - bone mass loss, 699, 700t–705t, 714
 - cataracts, 779–780, 782t–787t
 - COPD, 499
 - cost-of-smoking, 870
 - dental caries, 737, 738, 763t–766t
 - erectile dysfunction, 769, 770t, 771
 - glaucoma, 789
 - lung function decline, 475
 - macular degeneration, 786–787
 - medical services utilization, 647
 - peptic ulcer disease, 805–806
 - periodontal disease, 735, 742t–759t
 - respiratory disease
 - acute, 444, 449
 - chronic, 485, 488
 - smoking attributable mortality, 882
 - stomach cancer, 181
- CT. See Computed tomography (CT)**
- CVD. See Cardiovascular diseases; Specific disease**
- Cyclin D1 gene, 65, 117**
- CYP1A1 gene, 47, 309**
- CYP1A2 gene, 47, 308**
- CYP2A6 gene, 47**
- Cytochrome P-450 enzymes, 47, 211, 304, 308**
- Cytokines, in acute respiratory diseases, 427**

D

- DALE. *See* Disability-adjusted life expectancy (DALE)
 DALYs. *See* Disability-adjusted life years (DALYs)
 Danish Osteoporosis Prevention Study, 714
 Database, evidence, 9, 898
 Data sets, for smoking attributable mortality estimates, 880, 881t
 DCC gene, 180, 210
 Death
 fetal (*See* Stillbirth)
 infant (*See* Sudden infant death syndrome (SIDS))
 premature, from smoking-related disease, 873t, 885 (*See also* Smoking attributable mortality (SAM))
 prevention of, 871–876, 872t–873t, 875t
 sudden cardiac, 384–392
 epidemiologic evidence, 387
 Death certificates, disease burden estimates using, 879
 Denmark, Copenhagen City Heart Study, 449, 478, 491, 501
 Dental caries, 736–739
 biologic basis, 737
 conclusions, 29, 739
 epidemiologic evidence, 737–738, 763t–766t
 evidence synthesis, 738–739
 implications, 739
 Dental diseases, 732–739, 908–909. *See also* Periodontitis;
 Specific disease
 classification, 732, 735
 conclusions, 29, 732, 818
 Dental hygiene, and dental caries, 737, 738
 Dental plaque, bacterial, 733–734
 Diabetes mellitus, and erectile dysfunction, 768
 Diabetic retinopathy, 29, 788–789, 788t–791t, 796t–799t
 Diet
 colorectal cancer, 209, 214
 lung function decline, 478–479
 pregnancy outcome, 563
 prostate cancer, 250
 stomach cancer, 181, 183
 Diffuse parenchymal lung diseases, 503, 508
 Diminished health status, 615–697, 909
 biologic basis, 616–626, 900
 conceptual model, 616f
 conclusions, 8t, 29, 616, 617t–618t, 676–677, 818
 epidemiologic evidence, 626–669, 638t–645t, 648t–653t
 evidence synthesis, 669, 676
 implications, 677
 and medical services utilization, 646–653
 Disability, relative rate of, 865
 Disability-adjusted life expectancy (DALE), 855, 856t
 Disability-adjusted life years (DALYs), 855, 856t
 Disease burden, 9, 19, 30, 855–871, 876, 898. *See also*
 Economic costs
 COPD, 499
 current impact, 858–859
 estimation of, 878–887
 methodology, 878–879, 885–886
 implications, 877
 measurement of, 855, 856t–857t
 Disease classification, 858, 861, 880, 882, 883t, 886, 887
 DMFS index, 737, 738
 DMFT index, 737, 738
 DNA adducts, 44–45, 47, 49, 65, 168, 170, 210, 302, 304
 DNA repair capacity, and cancer susceptibility, 47, 65
 Dose-response relationship, 22. *See also* Pack-days; Pack-years
 abdominal aortic aneurysm, 396
 absenteeism, 627
 asthma, 491
 childhood, 487
 bladder and kidney cancer, 166
 brain cancer, 302–303
 breast cancer, 306–312
 cardiovascular disease, 366, 368–369, 370, 379, 385–386, 397
 carotid intimal-medial thickness (IMT), 372
 cataracts, 780
 cerebrovascular disease, 394
 cervical cancer, 169–170
 colorectal cancer, 210, 211–214, 240t–243t, 246t–249t
 congenital malformations, 576
 COPD mortality, 500
 dental disease, 735, 738
 endometrial cancer, 173
 erectile dysfunction, 771, 772
 esophageal cancer, 116, 118–119, 121t, 126t–127t
 fracture risk, 718
 Graves' ophthalmopathy, 801
 health status, self-rated, 668, 686t–689t
 infertility, 534–535
 laryngeal cancer, 62
 leukemia, 253–254
 leukocyte count, 626, 634t–637t
 lung cancer, 43–44, 48, 59–61
 lung development in utero, 467
 lung function decline, 481, 481f, 483f
 medical services utilization, 647, 652, 654t–661t
 oropharyngeal cancer, 64, 66, 102t–105t
 ovarian cancer, 171
 oxidative stress, 619
 pancreatic cancer, 137
 prostate cancer, 251
 reproductive effects, 532, 535, 539
 respiratory disease
 acute, 432, 438, 444, 449, 462
 chronic, 487–488
 SIDS, 584
 stomach cancer, 179, 179f, 180, 182, 192t–201t
 Down syndrome, 576
 DPC4 gene, 180
 Drusen, 781, 786
 Duodenal ulcer disease. *See* Peptic ulcer disease

E

EBCT. *See* Electron-beam computed tomography (EBCT)
Eclampsia, 553, 562t–563t. *See also* Preeclampsia
Econometric models, of cost-of-illness estimates, 869–870
Economic costs
 of COPD, 499
 measurement of, 868f, 868t
 medical care, 646, 654t–661t, 664t–669t
 fracture-related, 698
 smoking attributable, 9, 30, 855, 856t, 863–871, 869t, 876, 898
 and health policy goals, 877
 measurement of, 863–869, 868f, 868t
 net versus gross, 870–871
 offsets, 869–870
Ectopic pregnancy, 527
 conclusions and implications, 529t, 565, 575, 600
 epidemiologic evidence, 550–551, 551t–555t
Edinburgh Artery Study, abdominal aortic aneurysm, 396
Effect modification, 884
Elderly population
 fracture risk in, 698 (*See also* Bone mineral density (BMD); Fractures)
 self-rated health status in, 669
Electron-beam computed tomography (EBCT), 378
Emphysema, 472, 498
Employers, cost-of-smoking estimates for, 865, 871
Endometrial cancer, 172–173, 174t–177t, 906
 conclusions, 26, 172–173, 325
Endothelial dysfunction
 in atherosclerosis, 365–367, 370
 and erectile dysfunction, 768
Endothelial function, measurement of, 366
Environmental exposure. *See also* Occupational exposure;
 Passive smoking
 asthma, 491
 breast cancer, 309
 lung function decline, 480
 stomach cancer, 180
Epinephrine, 369
Epithelial dysfunction
 in colorectal cancer, 210
 in smoking-induced lung injury, 472, 472f
Epithelium, retinal pigment, 780
ErbB-2 gene, 180
Erectile dysfunction, 767–776, 909
 biologic basis, 768
 clinical data on, 772–773
 conclusions, 29, 767, 776, 818
 disease correlates, 771–772
 epidemiologic evidence, 768–776, 770t
 evidence synthesis, 776
 experimental data on, 774–776, 775t
 implications, 776
Erythroplasia, 64
Esophageal cancer, 116–119, 906
 biologic basis, 117–118

 conclusions, 4t, 26, 39, 40t, 61, 116–117, 119, 324
 epidemiologic evidence, 118–119, 120t–135t, 181
 evidence synthesis, 119
 implications, 119
 mortality rate, 116, 118, 119
Estrogen(s), 304–305, 309
Estrogen receptors, 171–172, 311
Estrogen replacement therapy, 20, 172, 214
Ethnic groups. *See also* Racial groups; Specific group
 breast cancer, 303
 cardiovascular disease, 364, 384–385
 cerebrovascular disease, 394–395
 colorectal cancer, 208–209
 COPD mortality, 500
 lung function decline, 475
 smoking prevalence among, 898
 stomach cancer, 178

Evidence

 classification of, 3
 companion database of, 9, 898
 evaluation of, 3, 10, 17
Experimental data, causal inference from, 17, 19, 22–23
Eye diseases, 777–789, 801, 909. *See also* specific disease
 conclusions, 29, 777, 818

F

Fatty streaks, 371
Federal Trade Commission (FTC), 49, 61, 324, 386, 502
Fertility, 533–540. *See also* Infertility; Pregnancy
 conclusions, 7t, 28, 541, 600
 epidemiologic evidence
 female, 534–539, 541t–548t
 male, 533–534, 536t–539t
 evidence synthesis, 536t–541t, 539–541, 565
 implications, 541, 575
Fetal death. *See* Stillbirth
FEV₁
 in adolescents who smoke, 473–474
 decline in, 474–475, 476t–479t, 478–480
 and lung development in utero, 469
 in respiratory disease
 acute, 449, 451, 453
 chronic, 463, 468f, 668f
Fibrinogen, 367–368, 370
Fibrinolysis, 367–368
Filter-tipped cigarettes. *See also* Nicotine yield; Tar yield
 brain cancer, 302–303
 chronic respiratory disease, 501
 epidemiologic studies of, 51, 56
 lung cancer, 49–51, 56–57, 59, 386
Finland
 abdominal aortic aneurysm study in, 396
 bone density studies in, 714
 cerebrovascular disease study in, 395
 chronic respiratory disease studies in, 502

- lower respiratory illness study in, 433
- self-rated health status study in, 663
- Follow-up studies. *See also specific study*
 - absenteeism, 627
 - atherosclerosis, 372
 - bladder and kidney cancer, 167
 - bone density, 716–717
 - breast cancer, 306
 - cataracts, 780
 - cerebrovascular disease, 394
 - colorectal cancer, 211, 213
 - congestive heart failure, 387
 - esophageal cancer, 118
 - leukemia, 253
 - medical services utilization, 652
 - oropharyngeal cancer, 65
 - peptic ulcer disease, 811
 - prostate cancer, 250–251
 - stomach cancer, 181–182
- Forced expiratory volume in one second (FEV₁). *See* FEV₁
- Former smokers. *See* Smoking cessation
- Fractures, 698–699, 717–719, 909
 - biologic basis, 698–699
 - conclusions, 8t, 29, 698, 719, 818
 - epidemiologic evidence, 717–718, 720t–731t
 - evidence synthesis, 718
 - implications, 719
 - relative risk, 698, 717–718, 717f
 - and smoking cessation, 718
- Framingham Study
 - chronic respiratory symptoms, 488
 - population-attributable risk in, 876
 - sudden cardiac death, 387
- France
 - asthma study in, 491
 - atherosclerosis study in, 378–379
- Fruit, fresh, intake of, 479

G

- Gastric cancer. *See* Stomach cancer
- Gastroesophageal reflux, 117
- Gastrointestinal physiology, effects of smoking on, 804–805
- Gastroschisis, 576
- Gender distribution
 - absenteeism, 637
 - acute respiratory disease, 449, 451
 - asthma, childhood, 487
 - bladder and kidney cancer, 166–167
 - brain cancer, 302
 - cancer mortality, 39, 42
 - cardiovascular disease, 364, 373, 387
 - cerebrovascular disease, 394–395
 - colorectal cancer, 208, 212–214

- COPD mortality, 500
- coronary heart disease, 384–385
- esophageal cancer, 116, 118
- leukemia, 252, 253
- liver cancer, 296
- lung cancer, 42, 58t, 59, 60f, 61, 324, 901
- lung development in utero, 468, 470t–471t
- lung function decline, 474–475, 480–481, 481f
 - in adolescents who smoke, 473–474
- macular degeneration, 786–787
- medical services utilization, 647
- oropharyngeal cancer, 63–64, 66–67
- respiratory disease, 433, 449
- smoking attributable mortality, 880, 881t, 882
- smoking prevalence rates, 859, 859t
- stomach cancer, 178, 179f, 180, 182
- General Electric study (United Kingdom), 627
- Generalizability, of cohort studies, 884
- Genetic factors
 - breast cancer, 303–304, 308–310, 312, 325, 900
 - leukemia, 253
 - lung cancer, 43, 44–47, 49
- Genetic mutations
 - asthma, 491
 - bladder and kidney cancer, 166
 - brain cancer, 302
 - breast cancer, 304, 309, 312, 325
 - and carcinogenesis, 45–47
 - cervical cancer, 168, 170
 - colorectal cancer, 210, 213
 - esophageal cancer, 64–65, 67
 - lung injury, 472–473
 - oropharyngeal cancer, 64–65, 67
 - pancreatic cancer, 136–137
 - stomach cancer, 180
- Genitourinary defects, congenital, 576
- Germany, peptic ulcer disease study in, 805
- Gestation. *See also* Pregnancy
 - shortened, 532–533, 555, 575, 600, 887
- Gestational age, small for. *See also* Intrauterine growth retardation (IUGR)
 - conclusions, 529t
 - incidence, 887
- Gingival blood flow, 734
- Gingivitis, 732–733
- Glaucoma, 29, 789, 800t
- Gliomas, 302–303
- The Global Burden of Disease (WHO)*, 855
- Glutathione S-transferase (GST), 211
- Graves' ophthalmopathy, 29, 801, 802t–803t
- Growth factors, in carcinogenesis, 117
- GST. *See* Glutathione S-transferase
- GSTM1 gene, 47, 211, 309
- Guidelines for the Diagnosis and Management of Asthma (NHLBI)*, 486

H

H. pylori infection. See *Helicobacter pylori* infection; Peptic ulcer disease

Hawaii
 Honolulu Heart Program, 478, 482, 669
 peptic ulcer disease study in, 806

Hazard ratio (HR), 879

HBV infection, 296–297

HDL. See High-density lipoprotein (HDL)

Health care costs. See Disease burden; Economic costs

Health Care Financing Administration, 867

Health Interview Study (1964–1965), 424

Health policy goals, for smoking reduction, 871–877, 872t–873t, 875t, 898–901

Health Professionals Follow-Up Study, 212, 214, 251, 769, 772

Health status, 615
 diminished (See Diminished health status)
 self-rated (See Self-rated health status)

Health status indicators, 615, 616f

Healthy People 2010, 30, 855, 871–876

Healthy smoker effect, 490

Heart complications, postoperative, 653

Heart defects, congenital, 576

Heart disease. See Cardiovascular diseases; Coronary heart disease; Specific disease

Heart failure, congestive, 387, 392

Heart rate, 369

Helicobacter pylori infection. See also Peptic ulcer disease
 and stomach cancer, 178, 180–181, 183, 325

Hemophilus influenzae infection, 449, 455

Hemostatic factors, 368, 370

Hepatitis, 296–297

Hepatocellular carcinoma, genetic mutations in, 46

Heterocyclic aromatic amines, 210

Heterozygosity, loss of, 46, 49, 65, 180

High-density lipoprotein (HDL), 368–369

Hill, Austin Bradford, 21, 23

Hip fractures. See Fractures

HIV infection
 and acute respiratory infections, 444, 445, 445t–446t
 and leukocyte count, 626

Hong Kong, adolescent smoking study in, 485, 487

Honolulu Heart Program, 478, 482, 669

Hormone(s). See also specific hormone
 female
 and breast cancer, 304–305, 309, 311
 and endometrial cancer, 172–173
 and ovarian cancer, 171
 male, 533
 and prostate cancer, 250

Hormone replacement therapy (HRT), 20, 172, 214

Horse-racing effect, 479

Hospitalization costs, smoking attributable fractions for, 869

Hospitalization rates, 647, 654t–669t

Human immunodeficiency virus (HIV) infection. See HIV infection

Human papilloma virus (HPV) infection, 167–170

Hume, David, 19

8-hydroxydeoxyguanosine (8-OH-dG), 619

8-hydroxyguanine, 619, 620t

Hypercholesterolemia, 366

Hyperfibrinogenemia, 367–368, 370

Hypersensitivity pneumonitis, 503

Hypertension, 369. See also Preeclampsia
 and cerebrovascular disease, 395
 and erectile dysfunction, 771

Hypoxemia, 370

I

IARC. See International Agency for Research on Cancer (IARC)

ICD. See International Classification of Diseases

IDF. See Incidence density fraction (IDF)

Idiopathic pulmonary fibrosis (IPF), 28, 503

IHD. See Ischemic heart disease

Immune function, 616
 acute respiratory diseases, 424–428, 425t–427t, 444
 periodontal disease, 734
 postoperative complications, 653

Implications, of causal conclusions, 18–19. See also specific disease or conclusion

Impotence. See Erectile dysfunction

“Inadequate” evidence category, 18

Incidence density fraction (IDF), 878

India, cataract study in, 779

Infancy
 lung function in, 463, 473–474
 passive smoking in, 463, 898
 smoking attributable mortality, 887

Infant birth weight
 low (See Low birth weight (LBW); Very low birth weight (VLBW))
 and smoking during pregnancy, 469

Infant mortality, 576–599. See also Stillbirth
 conclusions, 28, 531t, 599, 600
 epidemiologic evidence, 583–584, 585t–592t
 risk estimates, 858
 smoking attributable, 861, 862t, 887

Infertility, 527
 conclusions, 529t, 600
 confounding factors in, 535, 539
 definition of, 534
 epidemiologic evidence, 534–535, 539
 evidence synthesis, 565
 implications, 575
 primary, 534

- secondary, 534
treatment for, and smoking status, 539–540
- Inflammation**
asthma, 486
atherosclerosis, 368, 370
biological markers of, 368, 370, 626, 634t–637t
diffuse parenchymal lung disease, 508
diminished health status, 618–619, 626, 634t–637t
lung injury, 472, 472f
respiratory diseases, acute, 427–428, 444
- Influenza**, 424
and COPD, 449
epidemiologic evidence, 428–432, 429t–431t, 433t–437t
vaccination against, 432, 455
- Inpatient services.** See **Hospitalization rates**
- Institute of Medicine (IOM)**, 17–18, 51, 59
- Insurance premiums, and cost-of-illness estimates**, 870–871
- Interleukins, in acute respiratory diseases**, 427
- Intermittent claudication**, 371, 372
- International Agency for Research on Cancer (IARC)**, 18, 39, 46, 59, 137, 167, 183, 210, 252, 254, 297, 304, 858
- International Classification of Diseases**
7th Revision, 861, 883t
8th Revision, 861, 883t
9th Revision, 498, 861, 880, 883t, 887
10th Revision, 858, 861, 882, 883t, 887
- International Studies of Infarct Survival clinical trial**, 386
- Interstitial lung diseases**, 503, 508
- Intrauterine growth retardation (IUGR)**
conclusions and implications, 575, 600
epidemiologic evidence, 555, 564–565, 565t–574t, 573–575
estimates, 887
- In vitro fertilization (IVF)**, 539–540
- IPF.** See **Idiopathic pulmonary fibrosis (IPF)**
- Ischemic heart disease**, 384, 860t
- Ischemic stroke.** See **Cerebrovascular disease**
- Isoprostanes, as markers of oxidative injury**, 619, 622t–625t
- F₂-isoprostanes**, 369
- Italy**
cataract study in, 779
coronary heart disease study in, 386
erectile dysfunction study in, 769, 771
- J**
- Japan**
breast cancer study in, 311
cerebrovascular disease study in, 395
idiopathic pulmonary fibrosis study in, 503
peptic ulcer disease study in, 807
stomach cancer study in, 182

K

- Kaiser Permanente study**
cerebrovascular disease, 395
hospitalization rates, 647
leukemia, 253
leukocyte counts, 626
respiratory disease, chronic, 502
- Kidney cancer**, 166–167, 905
conclusions, 4t, 26, 39, 40t, 166–167, 324
- Korea, cerebrovascular disease study in**, 395
- K-ras gene**, 45, 136–137
- Krimpen Study**, 769
- K-sam genes**, 180

L

- Lacunar infarcts**, 373, 379
- Language (terminology)**, 10, 11t–17t, 17–18, 24
- Large cell carcinoma**, 43, 59
- Laryngeal cancer**, 62, 68t–97t, 906
conclusions, 4t, 25, 39, 40t, 61, 62, 324
- Latin America, cervical cancer study in**, 169
- LBW.** See **Low birth weight (LBW)**
- LDL.** See **Low-density lipoprotein (LDL)**
- Lead-210**, 252, 254
- Legionella pneumophila infection**, 432, 433t–437t, 444
- Leg symptoms, ischemic**, 371–372
- Leiomyosarcoma**, 180
- Leisure World cohort, colorectal cancer study in**, 213
- Lens opacity**, 778, 779
- Leukemia.** See **Acute leukemia**
- Leukemogens**, 252–254
- Leukocyte count**, 368, 370, 626, 628t–637t
- Leukoplakia**, 64–65, 67
- Levin's attributable risk.** See **Population-attributable risk (PAR)**
- Life expectancy**
extended, for former smokers, 869–870
of nonsmokers
versus smokers, 885
social welfare costs, 869–870
and smoking-related disease, 885
- Lifestyle, and coronary heart disease risk**, 386–387
- Limb defects, congenital**, 576
- Lip cancer**, 63. See also **Oropharyngeal cancer**
- Lipid metabolism**, 368–369
- Literature review**, 3
- Liver cancer**, 296–297, 298t–301t, 906
conclusions, 26, 296–297, 325, 900
mortality rate, 296
- Longevity.** See **Life expectancy**

Longitudinal studies

- asthma, 490, 492t–493t
 - atherosclerosis, 372, 379
 - esophageal cancer, 117
 - lung function decline, 474
 - respiratory disease, chronic, 502, 502t–505t
 - stomach cancer, 179f, 180
- Loss of heterozygosity (LOH), 46, 49, 65, 180
- Loss of periodontal attachment (LPA), 733, 735, 736
- Low birth weight (LBW), 527. *See also* Very low birth weight (VLBW)
- conclusions and implications, 7t, 528t, 574, 575, 600
 - definition of, 555
 - epidemiologic evidence, 564–565, 565t–574t
 - smoking attributable mortality, 887
 - studies of, confounding factors in, 533
- Low-density lipoprotein (LDL), 365–366, 368
- Lower respiratory illnesses (LRIs). *See also* specific disease conclusions, 424
- epidemiologic evidence, 432–444, 433t–443t
 - and lung development in utero, 468–469
 - risk for, versus upper respiratory illnesses, 445
- Lung cancer, 42–61
- biologic basis, 43–47, 900
 - biological markers of, 44–47, 49
 - conclusions, 4t, 25, 39, 41t, 42, 43, 61, 324
 - diagnosis of, 59–61
 - epidemiologic evidence, 48–60, 52t–58t, 60f
 - evidence synthesis, 61
 - histopathology of, 42–43, 59–60
 - implications, 61
 - incidence, 42
 - mortality rate, 39, 42, 58t, 61, 860t–861t, 901
 - smoking attributable mortality, 880, 885–886, 886t
- Lung development in utero, 467–469
- conclusions, 6t, 469
 - evidence synthesis, 469
 - implications, 469
- Lung disease. *See* Respiratory diseases; *Specific disease*
- Lung function
- decline in, 474–483
 - conclusions, 27–28, 482–483
 - epidemiologic evidence, 474–482, 476t–479t
 - evidence synthesis, 482
 - implications, 483
 - and smoking cessation, 467t, 480–482, 481f, 483f
 - in infancy and childhood, 6t, 27–28, 473–474
- Lung Health Study
- acute respiratory disease, 451
 - chronic respiratory disease, 489, 489f
 - lung function decline, 475, 478, 479, 480, 482, 484f
- Lung injury, pathogenesis of, 472–473, 472f
- Lutheran Brotherhood Cohort Study, 251, 254
- Lymphoma, 39, 180

M

- M1, 211
- Macula, 780
- Macular degeneration. *See* Age-related macular degeneration (AMD)
- Magnetic resonance imaging (MRI), of brain, in subclinical atherosclerosis, 373, 379, 382t–385t
- Maine, breast cancer study in, 306
- Malondialdehyde, 369
- Mammography, 311–312, 318t–319t
- Massachusetts
- breast cancer study in, 306
 - chronic respiratory disease study in, 488
 - lung function study in, 474
 - tobacco control program, 875
- Massachusetts Male Aging Study, 767, 770, 771, 772
- Master Settlement Agreement (1998), 863, 869
- Medicaid costs, smoking attributable fractions for, 868–869
- Medical care costs, 646, 654t–661t, 664t–669t, 698. *See also* Disease burden; Economic costs
- Medical Research Council (United Kingdom), 455
- Medical services utilization, 646–653, 654t–661t, 662t–663t
- Medical utilization rates, in COPD, 499
- Medications. *See also* specific drug
- and erectile dysfunction, 771
 - and peptic ulcer disease, 804–807, 810–811
- MEDLINE search
- cataracts, 778
 - colorectal cancer, 211
 - dental caries, 737
 - erectile dysfunction, 768
 - esophageal cancer, 118
 - oropharyngeal cancer, 65
 - peptic ulcer disease, 804
 - periodontal disease, 735
 - reproductive effects, 533
 - respiratory disease
 - acute, 423
 - chronic, 463
 - stomach cancer, 181–182
- Men. *See* Gender distribution
- fertility in (*See* Fertility)
- Menopause. *See* Postmenopausal women
- Menstruation, 305, 534
- Mental health, self-rated status, 668–669, 690t–697t
- Meta-analysis
- antibiotic prophylaxis for COPD, 453
 - bone density, 706t, 714, 716
 - cerebrovascular disease, 394
 - coronary heart disease, 385
 - erectile dysfunction, 769
 - fracture risk, 718, 720t–724t
 - leukemia, 253

peptic ulcer disease, 811
 reproductive effects, 534
 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK),
 60, 168
 Metronidazole, 812
 MI. *See* Myocardial infarction (MI)
 Michigan, acute respiratory disease study in, 444, 447,
 450t–454t, 462
 Microbiology
 of dental disease, 733–734, 736
 of peptic ulcer disease, 804–806
 Micronutrients, depletion of, 181, 183, 619
 Minority groups. *See* Ethnic groups; Racial groups; *Specific*
group
 Miscarriage. *See* Spontaneous abortion; Stillbirth
 Mismatch repair genes, 210
 Molecular epidemiology, and cancer, 39, 45–47, 61, 117,
 308
 Morbidity, 8t, 30, 855, 856t
 nonspecific, burden of, 677
 Mortality. *See* Smoking attributable mortality (SAM);
Specific disease
 MRI. *See* Magnetic resonance imaging (MRI)
 Multicenter studies
 abdominal aortic aneurysm, 396
 peptic ulcer disease, 812
 Multiple myeloma, 39
 Multiple Risk Factor Intervention Trial (MRFIT), 251, 394–
 395
 Multivariate analysis, in coronary heart disease risk
 assessment, 386–387
Mycobacterium tuberculosis infection, 433–434, 433t–437t
 Myeloid leukemia. *See* Acute leukemia
 Myocardial infarction (MI), 384. *See also* Coronary heart
 disease
 Myocardial perfusion, 369, 370, 378

N

N-acetyltransferase 2 (NAT2), 211
 Nasal mucociliary clearance, 425
 NAT1 gene, 47, 308–309, 312
 NAT2 gene, 47, 308–309, 312
 National Ambulatory Medical Care Survey (1985), 499
 National Cancer Institute (NCI), 858
 chronic respiratory disease study, 501
 Smoking and Tobacco Control Monograph Series, 49,
 51, 59, 880
 National Center for Chronic Disease Prevention and
 Health Promotion, 9
 National Center for Health Statistics (NCHS), 858
 National Eye Institute (NEI), 777
 National Health and Nutrition Examination Survey
 (NHANES III), 387, 499

National Health and Social Life Survey, 767
 National Health Interview Survey (NHIS), 499, 858, 859t,
 861, 865, 871, 880, 882, 884
 breast cancer, 311
 colorectal cancer screening, 214–215
 medical services utilization data, 652
 peptic ulcer disease data, 806
 self-rated health status data, 662, 669
 National Heart, Lung, and Blood Institute (NHLBI), 486
 National Hospital Discharge Survey (1984), 499
 National Library of Medicine, PubMed database. *See*
 MEDLINE search
 National Medical Expenditures Survey (NMES-2), 867–
 869, 868f
 National models, for cost-of-illness measurement, 868,
 868f
 National Mortality Followback Survey (NMFS), 387, 884,
 885
 National Toxicology Program, 118, 181
 Natural experiment, 22
 NCHS. *See* National Center for Health Statistics (NCHS)
 NCI. *See* National Cancer Institute (NCI)
 “Negative” evidence category, 18
 Netherlands
 bone density studies in, 714
 chronic respiratory symptom studies in, 488
 cost-of-smoking studies in, 870
 erectile dysfunction study in, 769
 influenza study in, 432
 lung function decline studies in, 481
 peptic ulcer disease study in, 807, 811
 Neural tube defects, 576
 New Hampshire, breast cancer study in, 306
 New Mexico, tobacco smoke biological markers study in,
 51
 New York
 asthma study in, 491
 cigarette type studies in, 51
 New Zealand
 peptic ulcer disease study in, 805
 self-rated health status study in, 668
 NHANES III. *See* National Health and Nutrition Examina-
 tion Survey (NHANES III)
 NHIS. *See* National Health Interview Survey (NHIS)
 Nicotine
 and carcinogenesis, 44, 45f, 168
 and cardiovascular function, 365, 369–370, 387
 fetal, 563
 diabetic retinopathy, 788
 and gastric physiology, 180
 and immune system, 424–428, 425t–427t, 444
 and periodontium, 734
 pharmacokinetics of, 616
 and reproductive system, 534, 551, 563, 574
 and wound healing, 653

Nicotine yield

- biological markers of, 50–51
- changing, and disease risk, 900
- and chronic respiratory disease, 501–502
- and coronary heart disease risk, 386, 388t–393t, 392
- and lung cancer, 49–51, 50f, 52t–57t, 56–57, 59, 61

Nitrates, 60

Nitric oxide, 366, 768

Nitrosamides, 302

Nitrosamines, 302

- tobacco-specific, 44, 60, 65, 136–137, 210

N-nitrosodiethylamine, 118, 166

NMES-2. *See* National Medical Expenditures Survey (NMES-2)

NMFS. *See* National Mortality Followback Survey (NMFS)

NNK (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone), 60, 168

Nocturnal penile tumescence (NPT), 772, 773, 774

Non-Hodgkin's lymphoma, 180

Nonmalignant oral diseases. *See* Dental diseases

Nonsmokers. *See also* Passive smoking

- absenteeism, 615, 626–627, 638t–645t, 648t–653t
- bone density, 714
- brain cancer, 302
- breast cancer, 304–305, 306–308, 310–311
- cardiovascular disease, 366–367, 369, 370, 373, 378, 386, 387, 392
- cervical cancer, 169
- colorectal cancer, 210, 212, 213, 216t–239t
- dental caries, 737
- endometrial cancer, 173
- erectile dysfunction, 775–776
- esophageal cancer, 118, 120t, 122t–127t
- fracture risk, 717–718, 717f
- health status (*See* Diminished health status)
- leukemia, 254
- leukocyte counts, 619, 626, 628t–637t
- life expectancy, 870, 885
- lung cancer mortality rate, 58t
- macular degeneration, 786
- medical services utilization, 646–647, 652–653, 654t–661t
- oropharyngeal cancer, 65–66
- ovarian cancer, 171
- oxidative stress, 619, 620t–625t
- pancreatic cancer, 136
- prostate cancer, 250, 255t–257t
- reproductive effects, 534–535
- self-rated health status, 662–663, 668–669, 678t–685t, 690t–697t
- stomach cancer, 179–181, 183, 184t–191t, 200t–201t, 206t–209t

Nonsteroidal anti-inflammatory drugs (NSAIDs)

- and colorectal cancer, 214
- and peptic ulcer disease, 804–807, 810–811

Norepinephrine, 369

Normative Aging Study, of chronic respiratory disease, 502

North Carolina

- absenteeism study in, 646
- breast cancer study in, 309

Norway

- acute respiratory disease study in, 449
- colorectal cancer study in, 212
- peptic ulcer disease study in, 810
- stomach cancer study in, 182

NPT. *See* Nocturnal penile tumescence (NPT)

Nurses Health Study, 212–213

- breast cancer, 308
- COPD, 499
- coronary heart disease, 385
- sudden cardiac death, 387

Nursing home costs, smoking attributable fractions for, 869, 871

Nutrition. *See* Diet

O

Obesity, and breast cancer, 306–307

Observational studies, causal inferences from, 17, 19–21

Obstructive lung disease. *See* Chronic obstructive pulmonary disease (COPD)

Occupational exposure

- brain cancer, 302
- lung cancer, 43, 59
- lung disease, 465t–466t
- lung function decline, 480

Ocular lens, 777

Office of Technology Assessment (OTA), 865

Office on Smoking and Health (CDC), 9, 735, 737

OM-85 BV, 455, 457, 460

Omphalocele, 577

Oncogenes, 210

Onset of smoking, age at. *See* Age at onset of smoking

Ophthalmopathy, Graves', 801, 802t–803t

Oral cavity cancer. *See* Oropharyngeal cancer

Oral cleft defects, 576, 583, 600

Oral contraceptives

- and breast cancer, 307
- and cerebrovascular disease risk, 395
- and endometrial cancer, 172
- and ovarian cancer, 171

Oral diseases. *See* Dental diseases; *Specific disease*

Oral hygiene, and dental caries, 737, 738

Oral smokeless tobacco. *See* Smokeless tobacco

Oregon

- disease burden estimates in, 879
- self-rated health status study in, 663
- tobacco control program, 875

Oropharyngeal cancer, 63–67, 906

- and alcohol consumption, 882–884
- biologic basis, 64–65
- conclusions, 4t, 25, 39, 41t, 61, 63–64, 67, 324
- epidemiologic evidence, 65–66, 98t–115t
- mortality rate, 63–64, 66–67

Osteoporosis. *See also* Bone mineral density (BMD)
 increased risk of, 698–699, 716–717
 Outpatient services, utilization of, 646–647, 654t–661t,
 664t–669t
 Ovarian cancer, 171–172
 conclusions, 26, 171–172, 325
 mortality rate, 171
 Overestimation, in smoking attributable mortality
 estimates, 882
 Oxidative stress, 618–619, 620t–625t, 626
 and macular degeneration, 781
 and ovarian cancer, 171
 in smoking-induced lung injury, 472, 472f
 Oxygen demand, increased, 369
 Oxygen supply, decreased, 369–371

P

Pack-days. *See also* Dose-response relationship
 and acute respiratory disease risk, 449
 and infertility, 534–535
 Pack-years. *See also* Dose-response relationship
 and absenteeism, 627
 definition of, 66
 Pancreatic cancer, 136–137, 906
 conclusions, 5t, 26, 39, 41t, 136, 137, 324
 epidemiologic evidence, 137, 138t–165t
 Papanicolaou smears, 167
 Papua New Guinea, bronchitis study in, 455
 PAR. *See* Population-attributable risk (PAR)
 Passive smoking, 3
 atherosclerosis, 366, 397
 breast cancer, 310–312
 cost-of-illness estimates, 869
 erectile dysfunction, 771, 776
 in infancy and childhood, 463, 898
 lower respiratory illnesses, 438
 mortality rate, 858, 861t, 885
 pregnancy outcome, 573, 592
 prevalence of, 897–898
 protection against, 899
 SIDS, 584, 593
 Paternal smoking, congenital malformations related to,
 576
 Pathobiological Determinants of Atherosclerosis in Youth
 (PDAY) Study, 378–379, 396
 Pathogens
 gastrointestinal, 804–806
 periodontal, 734, 736
 respiratory, 455
 Peak expiratory flow, 452
 Pelvic inflammatory disease, 550
 Penile-brachial index (PBI), 773
 Penile erection. *See also* Erectile dysfunction
 chemically induced, 773, 774
 Penile tumescence studies, 772–774

Penis
 vascular hemodynamics, 772–773
 vascular morphology, 773
 Peptic ulcer disease, 804–813, 909
 biologic basis, 804–805
 conclusions, 8t, 29, 804, 813, 818–819
 epidemiologic evidence, 806–812, 808t–809t, 814t–817t
 evidence synthesis, 812–813
 implications, 813
 trends in, 805–806
 Percutaneous coronary artery vascularization, 385–386
 Periodontitis, 732–758
 biologic basis, 733–735
 conclusions, 29, 736
 epidemiologic evidence, 735–736, 740t–762t
 evidence synthesis, 736
 implications, 736
 Peripheral arterial disease, 371–373, 380t–381t
 P16 gene, 46
 P53 gene, 46, 65, 117, 166, 180, 210
 Pharyngeal cancer. *See* Oropharyngeal cancer
 Photoreceptors, 780
 Physical activity, and colorectal cancer, 214
 Physical development, child. *See* Child development
 P16INK4a gene, 64, 117
 Pipe smoking
 esophageal cancer, 116–117
 health effects, 3
 oropharyngeal cancer, 63–64, 66, 67
 smoking attributable mortality, 882
 Placental abruption
 conclusions and implications, 565, 575, 600
 epidemiologic evidence, 553, 560t–561t
 Placenta previa
 conclusions and implications, 565, 575, 600
 epidemiologic evidence, 551, 553, 554, 557t–558t
 Platelet aggregation, 367–368, 370, 387
 Plausibility, 22
 Pneumococcal infection, and COPD, 451, 462
Pneumocystis carinii infection, 444
 Pneumonia, 424
 conclusions, 5t
 epidemiologic evidence, 432–438, 433t–437t
 in HIV-infected patients, 444, 445t–446t
 immune response markers in, 425
 Pneumonitis, hypersensitivity, 503
 Poland, stomach cancer study in, 181
 Polonium-210, 252, 254
 Polyaromatic hydrocarbons (PAHs), 44, 60, 210, 304, 309
 Population-attributable risk (PAR), 19, 855, 856t, 857–858,
 876, 878
 calculation of, 877–879
 in current smoking attributable mortality data, 859
 limitations of, 882–884
 Population-based studies, of erectile dysfunction, 769–771
 Population risk factors, disease burden elements used to
 evaluate, 855, 856t–857t

Postmenopausal women

- bone density studies, 698–699, 715f, 716–717
- breast cancer in, 305–308
- endometrial cancer in, 172
- fracture risk in, 717–718, 717f

Postoperative complications, 653, 670t–677t

Potentially Reduced Exposure Products (PREPs), 900

PPD. *See* Probing pocket depth (PPD)

Preeclampsia

- conclusions and implications, 575, 600
- epidemiologic evidence, 553, 562t–563t

Pregnancy (smoking during), smoking attributable mortality, 858, 860t, 861, 862t

Pregnancy (smoking during), 527, 550–576. *See also* Fertility; Infertility

- abnormalities caused by (*See* Congenital malformations)
- and atherogenesis, 365
- conclusions, 28, 575, 600
- epidemiologic evidence, 549–575
- evidence synthesis, 574–575
- implications, 575
- and lung function (*See* Lung development in utero)
- outcome studies of, confounding factors in, 565, 592–593
- and oxidative damage, 619
- prevalence of, 550, 858, 861

Pregnancy complications, 527. *See also* specific complication and cigarette type, 50

- classification, 887
- conclusions, 7t, 530t, 600
- confounding factors in, 532–533, 565
- epidemiologic evidence, 550–575
- evidence synthesis, 565–575
- implications, 575
- smoking attributable mortality, 858, 860t, 861, 862t, 885, 887

Premature deaths, from smoking-related disease, 873t, 885. *See also* Smoking attributable mortality (SAM) prevention of, 871–876, 872t–873t, 875t

Premature rupture of membranes (PROM), epidemiologic evidence, 564t–565t

Prenatal exposure. *See* Pregnancy (smoking during)

PREPs. *See* Potentially Reduced Exposure Products (PREPs)

Preterm delivery, 532–533, 554–555, 575, 600, 887

Preterm premature rupture of membranes (PROM) conclusions and implications, 565, 575, 600

- epidemiologic evidence, 554–555, 564t–565t

Probing pocket depth (PPD), 733, 735, 736

Productivity loss, smoking attributable, 865, 871, 876

Progesterone receptors, 311

Prostacyclin, 370

Prostate cancer, 250–252, 907

- biologic basis, 250, 900
- conclusions, 26, 250, 252, 325
- epidemiologic evidence, 250–251, 255t–257t

and erectile dysfunction, 771

mortality rate, 250–252, 255t–257t

Prostate-specific antigens (PSA), 251

Proteases, 472–473

Protein(s), oxidative damage to, 619, 620t

Protein C, 368

Pseudomonas infection, 449

Psychosocial factors

- in absenteeism studies, 637
- of disease burden, 871
- in self-rated health status, 668–669

Public health recommendations. *See also* Smoking reduction

- separation of causal claims from, 24
- trends in, 898–901

Public Health Service (U.S.), 871, 897, 899

Public opinion, and smoking prevention, 897

Public Summary, 898

PubMed database. *See* MEDLINE search

Puff volume, 60

Pulmonary fibrosis, idiopathic, 28, 503

Pulmonary function testing. *See also* specific test

- in adolescents who smoke, 473–474
- in COPD, 452, 456, 499
- in infants, and lung development in utero, 467–469

Q

Quality-adjusted life years (QALYs), 855, 856t

Quality of life

- and disease burden, 871
- and self-rated health status, 668
- and smoking cessation, 869–870

R

Racial groups. *See also* Ethnic groups; Specific group

- bladder and kidney cancer, 166
- breast cancer, 303
- cardiovascular disease, 364, 384–385
- cervical cancer, 167
- colorectal cancer, 208–209
- COPD mortality, 500
- esophageal cancer, 116
- lung cancer, 60f
- lung function decline, 475
- oropharyngeal cancer, 63
- smoking prevalence among, 898
- stomach cancer, 178

Radiation exposure

- and brain cancer, 302
- and leukemia, 252

Rancho Bernardo (California) Heart and Chronic Disease Study, 481

Randomization, 20

- Rapid acetylator genotype, 308
Ras mutations, 45, 136–137, 210
 Rectal cancer. *See* Colorectal cancer
Reducing Tobacco Use (USDHHS), 899
 Relative attachment loss, 733
 Relative measures, *versus* absolute, 884
 Relative risk (RR), 857–858, 878
 in smoking attributable mortality estimates, 858, 859, 863, 880, 882, 884, 885, 886–887
 Renal cell carcinoma, 166–167
 Reproductive effects, 525–601, 908. *See also* Fertility;
 Pregnancy (smoking during); *Specific effect*
 biologic basis, 532–533
 conclusions, 7t, 28, 527, 528t–532t, 600
 Reproductive risk factors, in breast cancer, 306–308
 Respiratory complications, postoperative, 653
 Respiratory diseases, 421–524, 907–908. *See also* specific disease
 acute (*See* Acute respiratory diseases)
 chronic (*See* Chronic respiratory diseases)
 conclusions, 5t–7t, 27–28, 508–509, 617t–618t
 smoking attributable mortality, 858, 860t, 862t, 882, 885, 886, 886t
 Respiratory distress syndrome (RDS), 887
 Respiratory symptoms, 485–508. *See also* Cough;
 Wheezing
 adulthood, 6t, 488–508
 childhood and adolescence, 6t, 485–488
 and lung function decline, 475
 Retina, effects of smoking on, 788, 789
 Reverse causality, 372
 Risk assessment. *See also* Attributable risk; Population-attributable risk (PAR)
 elements of, 857–858
 Risk factors, 19
 nonsmoking-related, and smoking attributable mortality estimates, 884
 population, disease burden elements used to evaluate, 855, 856t–857t
 Roswell Park Cancer Institute, 51
 Russia, stomach cancer study in, 181
- S**
-
- SAFs. *See* Smoking attributable fractions (SAFs)
 Saliva, composition of, and dental caries, 737
 SAM. *See* Smoking attributable mortality (SAM)
 SAMMEC. *See* Smoking-Attributable Mortality, Morbidity, and Economic Costs (SAMMEC)
 Sarcoidosis, 503
 Search strategies, 3
 SEER database. *See* Surveillance, Epidemiology, and End Results (SEER) database
 Self-rated health status, 662–663, 668–669
 dose-response relationship in, 668, 686t–689t
 in former smokers *versus* nonsmokers, 668–669, 690t–697t
 in nonsmokers *versus* smokers, 668–669, 678t–685t
 Seven Countries Study, 386, 395
 Seventh-Day Adventists study, 254, 499
 Sexually transmitted infections, 167–168
 Short Form 36 (SF-36), 662, 668
 Sickness absences. *See* Absenteeism
 SIDS. *See* Sudden infant death syndrome (SIDS)
 Silica exposure, 465t–466t
 Skeletal health. *See* Bone mineral density (BMD); Fractures
 Skin cancer
 conclusions, 39
 genetic mutations in, 46–47
 Skinfold thickness, and lung function decline, 479
 Slow acetylator genotype, 308, 312
 Small cell undifferentiated carcinoma, 43, 59
 Small for gestational age (SGA). *See also* Intrauterine growth retardation (IUGR)
 conclusions, 529t
 incidence, 887
 Smokeless tobacco
 oropharyngeal cancer, 63–67
 and risk of heart disease, 370–371
 smoking attributable mortality, 882
 Smoking and Tobacco Control Monograph Series (NCI), 880
 Smoking attributable fractions (SAFs), 855, 856t, 885
 for hospitalization costs, 869
 for Medicaid costs, 868
 for nursing home costs, 869
 Smoking-Attributable Mortality, Morbidity, and Economic Costs (SAMMEC), 19, 879, 880, 882, 884, 885, 886, 887
 Smoking attributable mortality (SAM), 9, 30, 39, 855, 856t, 857–858, 857t, 898
 calculation of, 861, 878–880, 885–886
 data sets for, 880, 881t
 current data, 858–861, 860t–861t, 876, 885–886, 886t
 former smokers, 873–874
 limitations of, 882–884
 previous estimates of, 884–886, 886t
 1999 state estimates, 863, 864t–867t
 total (1965–1999), 859–863, 862t
 Smoking cessation. *See also* Smoking reduction
 absenteeism, 636–637, 646, 648t–653t
 asthma, 490–491
 benefits of, 30, 855, 871–876
 bladder and kidney cancer, 166–167
 bone density, 714
 breast cancer, 304, 306–307, 311
 cancer, 39
 cardiovascular disease, 363–364, 369, 385–386
 cataracts, 779–780
 cerebrovascular disease, 394
 cervical cancer, 168, 169
 colorectal cancer, 210, 211, 213, 216t–239t, 246t–249t

- COPD morbidity, 502
- cost-of-illness offsets from, 869–870
- endometrial cancer, 172
- erectile dysfunction, 769, 771–772
- esophageal cancer, 117, 118–119, 120t, 122t–127t, 128t, 130t–133t
- and extension of life expectancy, 869–870
- fracture risk, 718
- Graves' ophthalmopathy, 801
- laryngeal cancer, 62
- leukemia, 253
- leukocyte count, 626, 632t–633t
- lung cancer, 43–44, 48–49, 48f, 61
- macular degeneration, 787
- medical services utilization, 647, 652, 664t–669t
- oropharyngeal cancer, 64–66, 106t–109t
- ovarian cancer, 171
- pancreatic cancer, 136, 137
- peptic ulcer disease, 804–805, 810, 811
- periodontal disease, 735
- and premature death, 873–874, 882
- prevalence of, 897
- prostate cancer, 251, 255t–257t
- respiratory disease
 - acute, 424
 - chronic, 467t, 486, 489
- self-rated health status, versus nonsmokers, 668–669, 690t–697t
- stomach cancer, 182–183, 184t–191t, 202t–209t
- Smoking prevalence, 9, 215, 897–898
 - during adolescence, 215, 859, 859t, 897–898
 - age distribution, 872–873, 872t–873t, 876
 - among ethnic and minority groups, 898
 - among women during childbearing years, 550
 - gender distribution, 859, 859t
 - during pregnancy, 550, 858, 861
 - rates, 859, 859t, 861, 880, 881t, 885
 - reduction of, health policy goals for, 871–877, 872t–873t, 875t
 - 1999 state estimates, 863
- Smoking reduction, 9, 30, 895–901. *See also* Smoking cessation
 - benefits of, 855, 871–876
 - conclusions, 9, 30
 - implications, 877
 - comprehensive approach to, 899
 - scientific foundation for, 899–900
 - social welfare and, 870, 897
 - sustained effort in, 898
 - trends in, 897, 901
- Smoking-related disease (SRD)
 - absenteeism caused by (*See* Absenteeism)
 - burden of (*See* Disease burden)
 - economic costs of (*See* Economic costs)
 - premature deaths from, 873t, 885, 898 (*See also* Smoking attributable mortality (SAM))
 - prevention of, 871–876, 872t–873t, 875t
- Smoking status. *See also* Dose-response relationship; Nonsmokers; Smoking cessation
 - and absenteeism, 627, 638t–645t, 648t–653t
 - and asthma, 490–491
 - and COPD mortality, 500
- Snuff, 64, 67
- Social welfare, and smoking control policies, 870, 897
- Societal values, and smoking prevention, 897
- Socioeconomic status (SES)
 - absenteeism, 637
 - breast cancer, 310
 - dental caries, 738
 - peptic ulcer disease, 807
 - reproductive effects, 532, 535
 - smoking prevalence, 898
- Sonoma (California) study, of chronic respiratory symptoms, 488
- Spain
 - bone density studies in, 714
 - peptic ulcer disease study in, 810
- Specificity, 22
- Sperm quality
 - epidemiologic evidence, 533–534, 536t–539t
 - evidence synthesis, 539–540
 - low, conclusions, 532t
- Spontaneous abortion, 527
 - conclusions and implications, 529t–530t, 565, 575, 600
 - epidemiologic evidence, 551, 556t–557t
- Squamous cell carcinoma
 - esophageal, 116, 117, 118, 119, 122t–127t, 130t–133t, 324
 - lung, 43, 59, 62
 - oropharyngeal, 64
- SRD. *See* Smoking-related disease (SRD)
- Stanford Five-City Project, 368
- States. *See also* individual states
 - cost-of-smoking damage claims, 869
 - smoking attributable mortality data, 863, 864t–867t, 879
 - smoking prevalence rates, 863
- Statistical association, 21
- Statistical inference, 10–24
 - approach to, 23–24
- Statistical strength, 21
- Stillbirth, 7t, 530t–531t
 - conclusions, 7t, 530t–531t
 - epidemiologic evidence, 583–584, 585t–592t
- Stomach cancer, 178–183, 907
 - biologic basis, 180–181
 - conclusions, 5t, 26, 178–179, 183, 325
 - epidemiologic evidence, 181–182, 184t–209t
 - evidence synthesis, 182–183
 - implications, 183
 - mortality rate, 178, 179f, 182–183
- Stomach dysplasia, 180
- Stroke. *See* Cerebrovascular disease
- Subarachnoid hemorrhage, 393, 394–395
- Subclinical atherosclerosis, 371–379
 - biological markers of, 372–373, 372t, 378–379, 382t–385t

- conclusions, 26, 379, 397, 407
- epidemiologic evidence, 371–379, 374t–379t
- evidence synthesis, 379
- implications, 379
- Substance abuse, and absenteeism, 637
- Substance P, 367
- Sudden cardiac death, 384–392
 - epidemiologic evidence, 387
- Sudden infant death syndrome (SIDS), 527, 533
 - conclusions and implications, 599, 600
 - epidemiologic evidence, 583–584, 585t–592t
 - smoking attributable mortality, 887
- “Sufficient” evidence category, 18
- “Suggestive” evidence category, 18
- Surgeon General’s report(s), 17
 - bone density loss, 698
 - cancer, 39, 40t–41t
 - cardiovascular disease, 397
 - causal inference in, 10–24
 - cigarette type, 51, 56
 - conclusions from, 3, 4t–8t, 25–30, 899–900
 - eye disease, 777
 - fracture risk, 698
 - lung cancer, 43
 - organization of, 9
 - preparation of, 9
 - smoking attributable mortality, 3, 9, 884–885
 - terminology in, 10, 11t–17t, 17–18, 24
- Surgeon General’s report (1964), 3, 25, 30
 - bladder and kidney cancer, 166
 - cancer, 39
 - cardiovascular disease, 363
 - cerebrovascular disease, 393
 - Criteria for Judgment, 10
 - erectile dysfunction, 767
 - laryngeal cancer, 62
 - lung cancer, 42, 43, 47, 48, 61
 - methodology, 10, 18–19, 21–23
 - oropharyngeal cancer, 63
 - peptic ulcer disease, 804
 - progress since, 897–898
 - reproductive effects, 527
 - smoking attributable mortality, 859, 861, 876, 884
 - stomach cancer, 179
- Surgeon General’s report (1967), cardiovascular disease, 363
- Surgeon General’s report (1968), lung cancer, 43
- Surgeon General’s report (1969), reproductive effects, 527
- Surgeon General’s report (1971)
 - cardiovascular diseases, 363
 - peptic ulcer disease, 804
- Surgeon General’s report (1972)
 - bladder and kidney cancer, 166
 - pancreatic cancer, 136
 - peptic ulcer disease, 804
- Surgeon General’s report (1974)
 - cardiovascular diseases, 363
 - stomach cancer, 179
- Surgeon General’s report (1978), reproductive effects, 527
- Surgeon General’s report (1979), 3, 885
 - acute respiratory diseases, 424
 - bladder and kidney cancer, 166
 - cardiovascular disease, 363
 - esophageal cancer, 118
 - pancreatic cancer, 136
 - peptic ulcer disease, 804
- Surgeon General’s report (1980)
 - bladder and kidney cancer, 166
 - reproductive effects, 527
- Surgeon General’s report (1981), lung cancer, 49
- Surgeon General’s report (1982)
 - bladder and kidney cancer, 166
 - cervical cancer, 168
 - esophageal cancer, 116
 - pancreatic cancer, 136
 - stomach cancer, 179
- Surgeon General’s report (1983)
 - abdominal aortic aneurysm, 396
 - cardiovascular diseases, 363
- Surgeon General’s report (1984)
 - chronic obstructive pulmonary disease, 501
 - chronic respiratory disease, 502
- Surgeon General’s report (1985), chronic respiratory diseases, 463
- Surgeon General’s report (1986), 3
- Surgeon General’s report (1989), 885
 - acute respiratory disease, 424
 - bladder and kidney cancer, 166
 - cerebrovascular disease, 394
 - cervical cancer, 168
 - endometrial cancer, 172
 - pancreatic cancer, 136
 - reproductive effects, 527
 - stomach cancer, 179
- Surgeon General’s report (1990), 3
 - acute respiratory disease, 424, 438, 444
 - bladder and kidney cancer, 166
 - cancer, 39
 - cardiovascular diseases, 363
 - cerebrovascular disease, 394
 - cervical cancer, 168
 - chronic obstructive pulmonary disease, 501
 - diminished health status, 616, 653
 - erectile dysfunction, 767
 - fracture risk, 718
 - leukemia, 252
 - liver cancer, 296
 - lung cancer, 43, 49
 - pancreatic cancer, 136
 - peptic ulcer disease, 804
 - stomach cancer, 179

- Surgeon General's report (1994), chronic respiratory symptoms, 485
- Surgeon General's report (1998)
 - cardiovascular diseases, 364
 - lung cancer, 43, 48
- Surgeon General's report (2000), 899
 - reproductive effects, 540
- Surgeon General's report (2001), 3
 - breast cancer, 303–304, 310
 - cancer, 39
 - cardiovascular diseases, 364
 - cervical cancer, 168, 169
 - colorectal cancer, 209
 - endometrial cancer, 172
 - fracture risk, 718
 - leukemia, 252
 - liver cancer, 296
 - lung cancer, 43, 48
 - ovarian cancer, 171
 - peptic ulcer disease, 804
 - reproductive effects, 540
- Surgeon General's report (2004), conclusions, 4t–8t
- Surveillance, Epidemiology, and End Results (SEER) database, 42, 59, 60f, 63, 116, 178
- Survivability, 21
- Sweden
 - abdominal aortic aneurysm study in, 396
 - bone density studies in, 714
 - cervical cancer study in, 169
 - childhood asthma study in, 487
 - colorectal cancer study in, 212–213
 - endometrial cancer study in, 173
 - leukemia study in, 254
 - prostate cancer study in, 251
 - smokeless tobacco study in, 370–371
- Switzerland
 - breast cancer study in, 310–311
 - peptic ulcer disease study in, 806

T

- T1, 211
- Taiwan, liver cancer study in, 297
- Tar yield
 - biological markers of, 50–51
 - changing, and disease risk, 900
 - coronary heart disease, 386, 388t–393t, 392
 - lung cancer, 49–51, 50f, 52t–57t, 56–57, 59, 61
 - oxidative stress, 619
 - respiratory disease
 - acute, 444
 - chronic, 501–502, 504t–507t
- TBARS. *See* Thiobarbituric acid reactive substances (TBARS)
- Tecumseh (Michigan) study, acute respiratory disease, 444, 447, 450t–454t, 462

- Teeth, diseases of. *See* Dental diseases; *Specific disease*
- Temporality, 22
 - and carcinogenesis, 215
 - and subclinical atherosclerosis studies, 372, 397
- Tennessee, reproductive effects study in, 535
- Terminology, 10, 11t–17t, 17–18, 24
- Testicular cancer, 39
- Testosterone, 250
- Thiobarbituric acid reactive substances (TBARS), 619, 622t–625t
- Thiocyanate, 778
- Th-2 lymphocyte phenotype, 428, 433, 444
- Thrombosis, 367–368, 387
- Tissue plasminogen activator (TPA), 367
- Tobacco control programs, 874–875, 877, 899. *See also* Smoking reduction
- Tobacco-specific nitrosamines, 44, 60, 210
- Tobacco use products. *See also* Cigarette type; Cigar smoking; Pipe smoking; Smokeless tobacco
 - and oral and pharyngeal cancer, 63–64, 66–67
 - and risk of heart disease, 370–371
- Transitional cell carcinoma, 166
- Tucson Epidemiological Study of Airways Obstructive Disease, 481–482
- Tumor suppressor genes, 46, 64–65, 117, 136, 166, 210. *See also specific gene*

U

- Ulcers. *See* Peptic ulcer disease
- Ultrasonography
 - carotid B-mode, in atherosclerosis studies, 374t–379t
 - of coronary calcium, 379
- Umbilical arteries, endothelial changes in, smoking-related, 365
- Underestimation, in smoking attributable mortality estimates, 881–882
- Unfiltered cigarettes. *See also* Nicotine yield; Tar yield and chronic respiratory disease, 501–502, 504t–507t
 - epidemiologic studies of, 51, 56
 - and lung cancer, 49–51, 56–57, 59
- United Kingdom. *See also under* British
 - absenteeism studies in, 627
 - breast cancer study in, 307
 - childhood asthma studies in, 487
 - chronic respiratory disease studies in, 502
 - chronic respiratory symptom studies in, 488–489
 - COPD studies in, 455
 - coronary heart disease study in, 386
 - idiopathic pulmonary fibrosis study in, 503
 - lung cancer studies in, 48f, 59
 - medical services utilization study in, 647
 - peptic ulcer disease study in, 805–807, 810
 - self-rated health status study in, 663
- United States military cohort study, of influenza, 432
- United States Physicians Study, cerebrovascular disease, 394

United States Public Health Service, 871, 897, 899
 United States Veterans Study, 396, 857
 Upper respiratory illnesses (URIs). *See also specific disease conclusions, 424*
 epidemiologic evidence, 438–444, 438t–443t
 risk for, versus lower respiratory illnesses, 445
 Urinary tract anomalies, congenital, 576
 Uterine arteries, endothelial dysfunction in, 365
 Uterine cancer. *See Cervical cancer; Endometrial cancer*

V

Vaccination, influenza, 432, 455
 Vascular endothelial growth factor (VEGF), 781
 Vascular hemodynamics
 and cardiovascular disease, 369
 and erectile dysfunction, 772–773
 and macular degeneration, 781
 Vasectomy, and prostate cancer, 250
 Very low birth weight (VLBW), 565. *See also Low birth weight (LBW)*
 Very low-density lipoprotein (VLDL), 368
 Veterans Administration
 bladder and kidney cancer studies, 167
 chronic respiratory disease study, 502
 colorectal cancer study, 213
 esophageal cancer studies, 117–118
 leukemia study, 253–254
 liver cancer study, 297
 lung cancer studies, 49
 medical services utilization study, 647
 oropharyngeal cancer study, 66
 peptic ulcer disease data, 805
 prostate cancer study, 250
 self-rated health status data, 663
 stomach cancer study, 182
 Veterans Study (U.S.), 396, 857
 Vietnam Experience Study, 772
 Visual system diseases. *See Eye diseases*
 Vitamin C
 and cataractogenesis, 778
 depletion of, 619

Vlagentwedde-Vlaardingen Study, 481
 VLBW. *See Very low birth weight (VLBW)*
 von Willebrand factor (vWF), 367–368

W

Washington state
 cervical cancer study in, 169
 endometrial cancer study in, 173
 Wheezing, 488
 in adolescents who smoke, 485
 and lung development in utero, 468
 and lung function decline, 475
 White blood cell count. *See Leukocyte count*
 Whitehall Study (United Kingdom), of chronic respiratory disease, 502
 White matter disease, 373, 379
 Wisconsin
 breast cancer study in, 306
 endometrial cancer study in, 173
 Women. *See Gender distribution*
 fertility in (*See Fertility; Pregnancy*)
 Women's Health Initiative Trial of HRT, 20
 Work loss, in cost-of-illness estimates, 865, 871, 876
 World Bank, 870
 World Health Organization (WHO), 534
 The Global Burden of Disease, 855
 The World Health Report 2002: Reducing Risks, Promoting Healthy Life, 886
 Wound healing, 653, 677t, 810–811

Y

Years of potential life lost (YPLL), 855, 856t
 calculation of, 857
 current, 858–859, 860t–861t
 data sets for, 880, 881t
 limitations of, 882–884
 Youth Risk Behavior Survey, 871

